AstraZeneca and Cellworks have announced a collaboration supported by the Wellcome Trust to speed the design of novel combination therapies for the treatment of drug-sensitive and resistant tuberculosis. This collaboration will also pave the way for the creation of platforms and approaches to handle Multi Drug Resistant Tuberculosis (MDR-TB), a condition that is reaching epidemic proportions in many developing parts of the world.
Current therapies for tuberculosis (TB) are based on creating combinations of three to four drugs and cycling through ad-hoc regimens, which are largely ineffective against MDR-TB. Together, Cellworks and AstraZeneca will pull from a pool of existing anti-infective drugs and attempt to find an effective combination with better efficacy and lower toxicity than the treatment regimens provided today.
Under this collaboration, Cellworks will use its proprietary predictive platform, which it pioneered in oncology and autoimmune disorders, to model drug MDR-TB and rationally identify ‘synergistic combinations’ that might have the highest efficacy and lowest possible toxic burden compared to all currently available combinations. AstraZeneca will then validate the top 10 most effective combinations identified by Cellworks in-vitro in its laboratories, followed by validation using in-vivo models.
Dr Anand Anandkumar, Managing Director, Cellworks Group India said, “Cellworks is honoured to take the lead on this unique drug development project which has the potential to save thousands of lives globally. Its results may also have positive implications in other infectious disease areas where drug resistance is prevalent.”
Dr Manos Perros, Head of the AstraZeneca Infection Innovative Medicines Unit, said, “Our continued investment in infectious disease research has positioned us to collaborate with organisations like Cellworks who share our passion for medical innovation. AstraZeneca would like to acknowledge and thank the Wellcome Trust for funding this important work.”
Dr Richard Seabrook, Head of Business Development at the Wellcome Trust, said, “MDR-TB is both a major global healthcare threat and a scientific challenge. Tackling it requires new approaches to drug discovery and we are delighted to be supporting this collaboration which has a strong mix of both innovation and drug development expertise.”
EP News Bureau – Mumbai